Suchergebnisse - "Rybicki, Lisa"

PubPharm (8)

1

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes

enthalten in: Journal of gastrointestinal cancer | 2017

von McNamara, M. | Adelstein, D. | Allende, D. | +10

2

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes

enthalten in: Journal of gastrointestinal cancer | 2016

von McNamara, M. | Adelstein, D. | Allende, D. | +10

3

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes

enthalten in: Journal of gastrointestinal cancer | 2016

von McNamara, M. | Adelstein, D. | Allende, D. | +10

4

Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes

enthalten in: International journal of gastrointestinal cancer | 2016

von McNamara, M. | Adelstein, D. | Allende, D. | +10

5

The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen

enthalten in: Journal of gastrointestinal oncology | 2016

von McNamara, M. | Rybicki, L. | Sohal, D. | +10

6

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

enthalten in: Investigational new drugs | 2011

von Adelstein, D. | Rodriguez, C. | Rybicki, L. | +2

7

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

enthalten in: Investigational new drugs | 2011

von Adelstein, D. | Rodriguez, C. | Rybicki, L. | +2

8

A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction

enthalten in: Investigational new drugs | 2011

von Adelstein, D. | Rodriguez, C. | Rybicki, L. | +2

1
[1]